Medicine and Dentistry
Adverse Outcome
7%
Antiinflammatory Activity
18%
Cardiovascular System
15%
Chronic Kidney Disease
18%
Clinical Intervention
18%
Cognitive Behavioral Therapy
12%
Comorbidity
8%
Congestive Heart Failure
62%
Coronary Artery Disease
26%
Cost-Effectiveness Analysis
18%
Cotransporter
18%
COVID-19
18%
Diabetes
39%
Diabetes Mellitus
23%
Diabetic Cardiomyopathy
18%
Diseases
24%
Drug Abuse
6%
Drug Therapy
6%
Early Intervention
24%
Early Intervention in Psychosis
18%
Early Psychosis
18%
Family Therapy
12%
Glycon
57%
Haloperidol
6%
Health Care Cost
12%
Heart Failure with Preserved Ejection Fraction
18%
Heart Failure with Reduced Ejection Fraction
18%
Heart Ventricle Remodeling
18%
Insulin Resistance
18%
Ischemic Heart Disease
18%
Left Ventricular Hypertrophy
55%
Lymphocyte
23%
Maturity Onset Diabetes of the Young
7%
Medical Science
18%
Mental Health
55%
Mental Health Service
6%
Neutrophil
23%
Olanzapine
6%
Oxidative Stress
7%
Patient Care
18%
Pediatrician
6%
Placebo
13%
Positive Syndrome
6%
Primary Percutaneous Coronary Intervention
18%
Proteomics
18%
Randomized Controlled Trial
18%
Recommended Drug Dose
6%
Recurrence Risk
12%
Secondary Prevention
18%
Social Participation
6%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
18%
Acute Heart Failure
23%
Adverse Outcome
18%
Antidiabetic Agent
5%
Antiinflammatory Activity
18%
Arginine
5%
Biological Marker
5%
Cardiovascular Disease
6%
Comorbidity
6%
Congestive Heart Failure
100%
Coronary Artery Disease
26%
Cotransporter
18%
Cytokine
5%
Dapagliflozin
23%
Diabetes Mellitus
23%
Diabetic Cardiomyopathy
18%
Disease Severity
6%
Glutathione
5%
Heart Failure with Preserved Ejection Fraction
18%
Heart Failure with Reduced Ejection Fraction
18%
Heart Left Ventricle Hypertrophy
55%
Heart Ventricle Remodeling
37%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
5%
Impaired Glucose Tolerance
5%
Inflammation
9%
Insulin Resistance
18%
Ischemic Heart Disease
18%
Ivabradine
18%
Kidney Disease
6%
Loop Diuretic Agent
7%
Metformin
57%
Nitric Acid Derivative
18%
Non Insulin Dependent Diabetes Mellitus
16%
Olanzapine
18%
Pharmacotherapy
18%
Placebo
31%
Proline
5%
Proteome
5%
Pyruvic Acid
5%
Randomized Controlled Trial
20%
Respiratory Tract Disease
6%
Risperidone
18%
Nursing and Health Professions
Acute Heart Failure
23%
Community Care
18%
Congestive Heart Failure
20%
Diabetes Mellitus
5%
Ivabradine
18%
Mental Health Care Personnel
18%
Metformin
18%
Neutrophil Lymphocyte Ratio
5%
Nitric Acid Derivative
18%
Practice Guideline
9%
